|
Products
Cancer – Multikine®
Multikine®, CEL-SCI's flagship cancer product, is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Multikine® is a different kind of weapon in the fight against cancer; one that harnesses the body's natural ability to fight tumors.
Multikine® is also the first of a new class of cancer immunotherapy drugs. It is the first combination immunotherapy possessing both passive and active properties. More...
Infectious Diseases - L.E.A.P.S.™
L.E.A.P.S.™ is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S.™ compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown in several animal models to preferentially direct immune response to a cellular (e.g. T-cell), humoral (antibody) or mixed pathway. Any disease for which antigenic epitope sequences have been identified, such as: infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer’s) are potential candidates for this technology platform. More...
|
